The impact of ustekinumab and tumor necrosis factor antagonists on extraintestinal manifestations of Crohn’s disease: a systematic review and meta-analysis
Mon-Jyh Lin, Ye-xin Chen, Tu-Nan Ding, Wei Han, Mo-han Sun, Dong Yi-yu, Ziqing Zheng, Yan Zhao 等 12 位
Beijing University of Chinese Medicine Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Zhejiang Chinese Medical University Tsinghua University
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Objective: Extraintestinal manifestations (EIMs) are commonly observed in patients with Crohn's disease (CD). Although Tumor Necrosis Factor (TNF) antagonists are commonly recommended for the management of several EIMs, their efficacy remains limited. Ustekinumab (UST), an alternative option after TNF antagonists failure, has shown potential efficacy for various EIMs. However, evidence regarding its effectiveness remains inconsistent. This study aimed to evaluate the efficacy and safety of UST and TNF antagonists for CD-related EIMs through a systematic review and meta-analysis. Methods: PubMed, Embase, and Cochrane Library were searched on 2 August 2025, to identify phase II and III randomized controlled trials (RCTs) evaluating UST or TNF antagonists in adults aged ≥18 years with moderate-to-severe active CD. The primary outcomes were EIMs and EIM-related symptoms. Two investigators, adhering to the PRISMA guidelines, independently screened the literature and extracted data. The risk of bias was assessed using the Cochrane Risk-of-Bias Tool 2.0. Random-effects and fixed-effect models were used to estimate pooled treatment effects. Results were presented using risk ratios (RRs), incidence rate ratios (IRRs) and 95% confidence intervals (CIs). Results: A total of 23 RCTs, involving 7,810 patients, were included, with EIMs such as fatigue, joint pain, and skin manifestations being considered. The meta-analysis revealed that UST significantly reduced the risk of fatigue in CD patients (IRR 0.53, 95% CI 0.33-0.84, P = 0.008). During maintenance therapy, UST treatment was significantly associated with a reduction in the risk of arthritis/arthralgia (IRR 0.56, 95% CI 0.36-0.86, P = 0.008). Weekly adalimumab (ADA) treatment was significantly associated with an increased risk of fatigue (IRR 2.79, 95% CI 1.12-6.94, P = 0.028). Conclusion: UST showed potential advantages in the management of fatigue and arthritis/arthralgia. ADA and infliximab (IFX) were not associated with statistically significant benefits for most analyzed EIM outcomes. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251111502, identifier CRD420251111502.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Inflammatory Bowel Disease
Rheumatoid Arthritis Research and Therapies · Spondyloarthritis Studies and Treatments